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Abstract Several botulinum toxin (BT) drugs are
licensed for the treatment of cervical dystonia (CD). We
wanted to compare the efficacy and the potency labelling of
incobotulinumtoxinA (Xeomin) and onabotulinumtoxinA
(Botox) by analysing the duration of their therapeutic
effect in a cross-over study. For this we studied 40 CD
patients (26 females, 14 males, age at therapy onset
52.6 ± 12.0 years, duration of dystonia at therapy onset
10.0 ± 9.2 years, Tsui score 9.1 ± 3.9) who first received
Botox and then Xeomin for at least 4 injection series
each. BT doses were exchanged based on a 1:1 conversion
ratio. Altogether 1,101 treatment cycles were evaluated.
For each patient 27.5 ± 13.1 treatment cycles were
recorded. Patients received 18.4 ± 12.4 treatment cycles
with Botox and 9.2 ± 4.5 with Xeomin. The treatment
duration (TD) throughout the treatment course was
11.3 ± 1.0 weeks (Botox 11.2 ± 1.1 weeks, Xeomin
11.4 ± 1.3 weeks). The interinjection interval (II)
throughout the treatment course was 14.8 ± 1.9 weeks
(Botox 14.7 ± 1.6 weeks, Xeomin 15.0 ± 2.2 weeks).
The mean difference between Botox and Xeomin was
0.3 weeks for TD (two-sided 95 % confidence interval [-
0.3; 0.9]) and 0.5 weeks for II (two-sided 95 % confidence
intervals [-0.4; 1.4]). The confidence intervals of both
parameters were within the predefined therapeutic equiva-
lence range set to ±1.5 weeks, thus indicating similar
efficacy of both BT drugs. Having based the exchange of
Botox and Xeomin on a conversion factor of 1:1 our
data confirm previous findings of an identical potency
labelling of both products, thus allowing comparisons of
efficacy, adverse effects and costs.
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Introduction
Botulinum toxin (BT) is generally accepted as therapy of
choice for the treatment of cervical dystonia (CD). Several
BT drugs are licensed for this indication. Onabotulinum-
toxinA (Botox) was the first drug used for CD treatment.
It is generally recognised as the gold standard for com-
parative studies. IncobotulinumtoxinA (Xeomin) was
introduced recently and features immunological advanta-
ges (Dressler 2012). Whenever a drug becomes available it
is interesting to compare its efficacy with existent ones. For
BT drugs, additionally, the issue of potency labelling needs
to be raised (Marsden 1993). We, therefore, wanted to
compare the efficacy as well as the potency labelling of
Botox and Xeomin by analysing the duration of their
therapeutic effect in a cross-over study.
Methods
Design
The study followed a prospective open label cross-over
design and was approved by the local ethical committee.
All patients in our BT outpatient clinics receiving BT
therapy for CD were monitored for the treatment duration
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(TD) and interinjection intervals (II). Those who were
initially treated with Botox and were later switched to
Xeomin were randomly included in this study until
n = 40 were reached.
Definitions
Injection series is the set of BT injections given at one
appointment. Treatment cycle is the treatment between two
subsequent BT injection series. Treatment course is the
time between the first and the last injection series recorded
in one patient. TD describes the time between the BT
application and the onset of the decrease of the therapeutic
effect as reported by the patient. II describes the time
between two subsequent BT injection series.
Patients
All patients in our BT outpatient clinics fulfilling the fol-
lowing inclusion criteria were included in the study: (1) BT
therapy with Botox for CD. CD severity was measured on
the Tsui scale (Tsui and Calne 1988). Additional dystonia
manifestations including periocular, oromandibular and
shoulder girdle muscles were allowed. (2) Botox appli-
cation for C4 injection series. (3) Exchange of Botox to
Xeomin. (4) Subsequent BT therapy with Xeomin for
C4 injection series.
BT therapy
BT therapy was performed with Botox (Pharm-Allergan,
Ettlingen, Germany) and Xeomin (Merz Pharmaceuticals,
Frankfurt/M, Germany) in dilutions of 100 MU per 2.5 ml
of 0.9 % NaCl/H2O. Botox
 doses were exchanged to
Xeomin doses using a 1:1 conversion ratio (Dressler et al.
2012). Mixtures of Botox and Xeomin were not applied.
Target muscle selection was based upon analysis of the
individual dystonic muscle involvement. Target muscles of
the neck included sternocleidomastoideus, splenius capitis,
semispinalis capitis, trapezius (cervical part), trapezius
(horizontal part), scalenii and levator scapulae muscles.
The BT dosing for each target muscle followed interna-
tionally accepted guidelines as previously published
(Benecke et al. 2003). Regular II was 12–14 weeks.
Re-injections were modified according to the patient’s
needs or requests. Spontaneous postponement by the
patient was allowed. Under exceptional circumstances II
could be reduced to 8 weeks.
Parameters
Demographic data collected for each patient included age
at therapy onset, sex, duration of dystonia at therapy onset
and Tsui score. Treatment data included II between all
injection series, total BT dose given at each injection series
and general remarks. Outcome parameter was the TD of
each injection series as reported by the patient at each re-
injection appointment.
Statistics
Two-sided 95 % confidence intervals were calculated to
assess the therapeutic equivalence for TD and II. The




Altogether 40 patients (26 females, 14 males, age at ther-
apy onset 52.6 ± 12.0 years, duration of dystonia at ther-
apy onset 10.0 ± 9.2 years) were evaluated in the study.
CD severity was 9.1 ± 3.9 on the Tsui scale.
General
Altogether 1,101 treatment cycles were evaluated in the 40
patients monitored in this study. For each patient
27.5 ± 13.1 treatment cycles were recorded. This is
equivalent to an average treatment course of approximately
7 years. The maximal number of treatment cycles was 66
covering a treatment course of approximately 17 years, and
the minimal 10 covering a treatment course of approxi-
mately 2.5 years. Patients received 18.4 ± 12.4 treatment
cycles with Botox and 9.2 ± 4.5 with Xeomin. The
average BT dose applied was 295.7 ± 96.1 MU of either
Botox or Xeomin.
Treatment duration
TD throughout the treatment course was 11.3 ± 1.0
(minimum 7.8 ± 1.4, maximum 21.0 ± 3.9) weeks. When
patients received Botox TD was 11.2 ± 1.1 (minimum
7.9 ± 1.5, maximum 20.5 ± 4.3) weeks, and under Xeo-
min it was 11.4 ± 1.3 (minimum 7.8 ± 1.4, maximum
22.3 ± 2.2) weeks. The mean difference between Botox
and Xeomin was 0.3 weeks (two-sided 95 % confidence
interval [-0.3; 0.9]). The confidence interval was within
the therapeutic equivalence range of ±1.5 weeks, thus
indicating similar efficacy of both BT drugs. Figure 1
shows the average of all TD before and after the patients
were switched from Botox to Xeomin. Only data points
with four or more contributing patients are included. There
is no obvious increase or decrease of TD throughout the
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treatment course. In 30 out of 40 patients (75 %), we found
TD B12 weeks; in 12 out of the 40 patients (30 %), TD
B10 weeks.
Interinjection intervals
II throughout the treatment course was 14.8 ± 1.9 (mini-
mum 11.3 ± 1.3, maximum 26.2 ± 7.7) weeks. When
patients received Botox II was 14.7 ± 1.6 (minimum
11.5 ± 1.5, maximum 24.9 ± 5.5) weeks, and under
Xeomin it was 15.0 ± 2.2 (minimum 10.4 ± 1.1, maxi-
mum 26.5 ± 1.3) weeks. The mean difference between
Botox and Xeomin was 0.5 weeks (two-sided 95 %
confidence intervals [-0.4; 1.4]). The confidence interval
was within the therapeutic equivalence range of
±1.5 weeks, thus, again, indicating similar efficacy of both
BT drugs. Figure 1 shows the average of all II before and
after the patients were switched from Botox to Xeomin.
Only data points with four or more contributing patients are
shown. There is no obvious increase or decrease of II
throughout the treatment course.
Discussion
With 1,101 injection series evaluated and 27.5 ± 13.1
treatment cycles (appr. 7 years) monitored in each patient,
this study is one of the most comprehensive studies of its
kind. Documentation of all patients by only two observers
(DD, FAS) throughout the complete observation period is
another unique feature of this study.
With II of 14.8 ± 1.9 weeks patients included in this
study were treated according to current guidelines recom-
mending II of more than 12 weeks to avoid BT antibody
formation. Subsequently, none of the patients studied
developed BT antibody-induced therapy failure (Dressler
2004) during the treatment course.
TD was 11.3 ± 1.0 weeks. Throughout the treatment
course TD does not show increase or decrease confirming
previously described lack of tachyphylaxia and induction
in BT therapy. Long-term reproducibility of the BT
response with constant TD is one of the most surprising
features of BT therapy. In 30 out of 40 patients (75 %), we
found TD B12 weeks; in 12 out of the 40 patients (30 %),
TD B10 weeks. This confirms the need to consider
decreasing II to avoid considerable time periods of sub-
optimal treatment.
Comparison of the therapeutic response to Botox and
to Xeomin produced TD of 11.2 ± 1.1 weeks and 11.4 ±
1.3 weeks, respectively, and II of 14.7 ± 1.6 weeks and
15.0 ± 2.2 weeks, respectively. With two-sided 95 %
confidence intervals of both parameters falling within the
therapeutic equivalence range set to ±1.5 weeks, similar
efficacy of both BT drugs is indicated. Having based the
switch from Botox to Xeomin on a conversion factor of
1:1 confirms previous findings of an identical potency
labelling of both products (Benecke et al. 2005; Dressler
2009; Dressler et al. 2012), thus allowing comparisons of
efficacy, adverse effects and costs.
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